Literature DB >> 11241230

Breast carcinomas of limited extent: frequency, radiologic-pathologic characteristics, and surgical margin requirements.

D R Faverly1, J H Hendriks, R Holland.   

Abstract

BACKGROUND: Clinical trials established the value of breast-conserving treatment (BCT) including the macroscopic removal of the tumor followed by local radiation therapy (RT) for Stage I and II invasive carcinomas. The occurrence of local tumor recurrence is related to the extent and multifocality of the tumor. Various studies aim to identify those tumors that could be proper candidates for conventional BCT. Furthermore, recent studies have focused on the identification of tumors that may be treated by breast-conserving surgery alone without RT. Small, localized tumors theoretically should be the potential candidates for this type of treatment. The mammographic and pathologic criteria for the identification of tumors with limited extent are not yet established; furthermore, the optimal extent of the surgical excision and the method for margin examination are controversial.
METHODS: Surgical breast-conserving procedures were simulated in a review of 135 mastectomy specimens of patients treated for an invasive carcinoma (> or = 4 cm in size, all pathologic types except invasive lobular carcinoma) who were theoretically eligible for conservative treatment. Tumor spread including possible multifocality and multicentricity was studied by the technique of correlated specimen radiography and pathology. Breast carcinoma of limited extent (BCLE), the proper tumor profile for BCT, was defined as having no invasive carcinoma, ductal carcinoma in situ, and lymphatic emboli foci beyond 1 cm from the edge of the dominant mass.
RESULTS: Fifty-three percent of the patients in this series had a BCLE. No statistically significant relation was found between BCLE and patient age, pathologic size, type and grade of the tumor, lymph node status, mode of detection, and mammographic aspect of the index tumor. Based on mammography, the absence of calcification or tumor density beyond the edge of index tumor appears to be the best predictor for BCLE (P < 0.0001). A 1-cm microscopically tumor free margin as the outer rim of a macroscopic surgical margin of 2 cm gives the best positive predictive value based on pathology (P < 0.0001). By applying the above conditions, 72 of the 135 cancers were identified as being potential BCLE cases in this series. However, whereas 64 of these 72 tumors (89%) were correctly identified as being true BCLE, 8 (11%) were erroneously identified as such (non-BCLE cases), having "residual" tumor foci beyond 2 cm from the edge of the dominant tumor.
CONCLUSIONS: We conclude, that approximately 50% of invasive ductal carcinomas may have limited extent. The accuracy of identifying this group of cancers, the proper candidates for BCT, by applying state-of-the-art mammography and pathology may be as high as 90%. A subset of these tumors might represent the potential candidates for treatment with surgery alone without RT. As a result, the routine application of BCT complemented by RT would have led to the overtreatment of 89% of the patients with a BCLE in this series; conversely, 11% of the tumors may have recurred without the use of RT. Considering that these conclusions are based on a theoretic morphologic model, further clinical studies with facilities for high quality team approach in diagnosis and therapy are needed to evaluate the impact of BCLE on BCT strategies. The results of this study should not justify the withholding of RT outside the context of clinical trials. Copyright 2001 American Cancer Society.

Entities:  

Mesh:

Year:  2001        PMID: 11241230     DOI: 10.1002/1097-0142(20010215)91:4<647::aid-cncr1053>3.0.co;2-z

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  26 in total

1.  Contrast-enhanced MRI in breast cancer patients eligible for breast-conserving therapy: complementary value for subgroups of patients.

Authors:  Eline E Deurloo; William F A Klein Zeggelink; H Jelle Teertstra; Johannes L Peterse; Emiel J Th Rutgers; Sara H Muller; Harry Bartelink; Kenneth G A Gilhuijs
Journal:  Eur Radiol       Date:  2005-11-19       Impact factor: 5.315

Review 2.  Advances in breast imaging: magnetic resonance imaging.

Authors:  Lia Bartella; Elizabeth A Morris
Journal:  Curr Oncol Rep       Date:  2006-01       Impact factor: 5.075

Review 3.  The role of radiological-pathological correlation in diagnosing early breast cancer: the pathologist's perspective.

Authors:  Tibor Tot; László Tabár
Journal:  Virchows Arch       Date:  2010-11-03       Impact factor: 4.064

Review 4.  Partial breast irradiation: a review of techniques and indications.

Authors:  A J Stewart; A J Khan; P M Devlin
Journal:  Br J Radiol       Date:  2010-03-11       Impact factor: 3.039

5.  Four-dimensional computed tomography in accelerated partial breast irradiation planning: single series from a phase III trial.

Authors:  Icro Meattini; Livia Marrazzo; Margherita Zani; Fabiola Paiar; Stefania Pallotta; Gabriele Simontacchi; Marta Bucciolini; Lorenzo Livi
Journal:  Radiol Med       Date:  2015-04-24       Impact factor: 3.469

Review 6.  Intraoperative Electron Radiotherapy (IOERT) in the Treatment of Primary Breast Cancer.

Authors:  Julia Kaiser; Roland Reitsamer; Peter Kopp; Christoph Gaisberger; Michael Kopp; Thorsten Fischer; Franz Zehentmayr; Felix Sedlmayer; Gerd Fastner
Journal:  Breast Care (Basel)       Date:  2018-05-30       Impact factor: 2.860

7.  Role of specimen US for predicting resection margin status in breast conserving therapy.

Authors:  M Moschetta; M Telegrafo; T Introna; L Coi; L Rella; V Ranieri; A Cirili; A A Stabile Ianora; G Angelelli
Journal:  G Chir       Date:  2015 Sep-Oct

Review 8.  Accelerated partial breast irradiation after conservative surgery for breast cancer.

Authors:  Henry M Kuerer; Thomas B Julian; Eric A Strom; H Kim Lyerly; Armando E Giuliano; Eleftherios P Mamounas; Frank A Vicini
Journal:  Ann Surg       Date:  2004-03       Impact factor: 12.969

9.  The serum protein alpha 2-Heremans-Schmid glycoprotein/fetuin-A is a systemically acting inhibitor of ectopic calcification.

Authors:  Cora Schafer; Alexander Heiss; Anke Schwarz; Ralf Westenfeld; Markus Ketteler; Jurgen Floege; Werner Muller-Esterl; Thorsten Schinke; Willi Jahnen-Dechent
Journal:  J Clin Invest       Date:  2003-08       Impact factor: 14.808

Review 10.  Obtaining adequate surgical margins in breast-conserving therapy for patients with early-stage breast cancer: current modalities and future directions.

Authors:  Rick G Pleijhuis; Maurits Graafland; Jakob de Vries; Joost Bart; Johannes S de Jong; Gooitzen M van Dam
Journal:  Ann Surg Oncol       Date:  2009-07-17       Impact factor: 5.344

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.